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day until disease progression or unacceptable toxicity. Dose reductions 
(50mg increments) were allowed as required. The NCI-CTC v3.0 was 
used to assess toxicities, including: incidence and grade of erlotinib-
related rash; serious AEs (SAEs) and treatment-related SAEs; and AEs 
leading to treatment withdrawal. Other treatment-related AEs were 
reported if they were not included on a list of 15 pre-speciﬁed AEs in 
the study protocol (rash; pruritis; dry skin; diarrhea; nausea; vomiting; 
stomatitis; abdominal pain; fatigue; dyspnoea; cough; anorexia; infec-
tion; conjunctivitis; and keratoconjunctivitis sicca).
Results: 885 patients were included in the analysis at the data cut-off 
(20/11/06) from Taiwan (n=297), mainland China (n=248), Hong Kong 
(n=160), South Korea (n=146), Thailand (n=30), Indonesia (n=2) and 
Malaysia (n=2). The median age was 61 years (range 22-95). Patient 
characteristics included: male 55%, female 45%; stage IIIB 20%, stage 
IV 79% (no data 1%); ECOG PS 0 15%, PS 1 67%, PS 2 14%, PS 3 
4%; non-smoker 52%, ever-smoker 47% (no data <1%); adenocarcino-
ma 68%, squamous-cell carcinoma 19%, other 13%; erlotinib 1st line 
11%, 2nd line 55%, 3rd line 33%, other <1%. Data on the occurrence 
of rash were available for 882 patients, 83% of whom experienced rash, 
mostly grade 1/2 (88% of those with rash). Adverse event (AE) safety 
data were available for 598 patients, 54% of whom experienced at least 
one AE. 19 patients (3%) had treatment-related SAEs, most commonly 
gastrointestinal (GI) disorders (1%), including abdominal pain (n=2), 
diarrhoea (n=5) and gastric ulcer haemorrhage (n=1). 17% of patients 
had at least one other treatment-related AE that was not pre-speciﬁed 
(3% had at least one grade 3/4 event); mucosal inﬂammation occurred 
in 3% of patients (<1% grade 3/4), but no other single event occurred 
in more than 2% of patients. Treatment-related interstitial lung disease 
(ILD; grade 2) was suspected in one patient, but this event was not re-
ported as an SAE and did not lead to treatment withdrawal; the patient 
continued on erlotinib until disease progression. 18 patients (3%) had 
at least one treatment-related AE leading to withdrawal of erlotinib; the 
most common such events were rash (4 patients), diarrhoea (3 patients) 
and pneumonitis (3 patients). Among 589 patients with available data, 
76 (13%) required dose reduction due to a treatment-related event, 
mainly rash (n=57). Efﬁcacy data will be presented.
Conclusions: Safety data for the E/SE Asian patient population in 
TRUST support the safety proﬁle of erlotinib seen in clinical trials. The 
incidence of ILD and ILD-like events is <1%, which is in-keeping with 
what has been seen with erlotinib universally. In the ‘real-life’ clinical 
setting, erlotinib is well tolerated, with full therapeutic doses adminis-
tered to the majority of patients. 
PD3-2-7 Molecular Targeted Therapy: EGFR inhibitors, Thu, 12:30 - 14:15
Implications of tumour cavitation on response assessment in 
trials of Vascular Endothelial Growth Factor Receptor (VEGFR) 
Inhibitors in combination with platinum-based chemotherapy for 
advanced non-small cell lung cancer (NSCLC): An analysis of trials 
conducted by the National Cancer Institute of Canada Clinical 
Trials Group (NCIC CTG). 
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Introduction: Inhibition of angiogenesis has shown promise in a 
variety of solid tumours. In NSCLC, the addition of bevacizumab to 
platinum-based doublet chemotherapy has led to a modest improve-
ment in survival in highly selected patients (pts). Antiangiogenic agents 
may be associated with cavitation of tumours, felt possibly due to 
ischemic necrosis; in the lung, this may lead to air-trapping and subse-
quent enlargement of the target lesion, which may lead to difﬁculties 
with assigning overall best response as well as date of progression. The 
NCIC CTG has conducted a number of studies of VEGFR inhibitors as 
single agent or in conjunction with standard chemotherapy regimens in 
a number of tumour types, including NSCLC.
Methods: Two phase I studies enrolled ﬁrst line NSCLC patients to es-
calating doses of a VEGFR inhibitor in combination with either standard 
carboplatin / paclitaxel or cisplatin / gemcitabine regimens. The control 
arm of a large phase II/III study of the same regimen of carboplatin and 
paclitaxel with identical entry criteria was used as a historical control. In 
all trials, response was assessed by RECIST every second cycle, radiol-
ogy reports were reviewed centrally conﬁrming response, progression 
and evidence of cavitation, while an independent response review has 
been conducted for one phase I study, where possible for all patients 
with cavitation noted in radiology reports, and is ongoing for the second 
phase I study. Pts showing cavitation had, in addition, an ‘exploratory’ 
response assessment in which the longest diameter of the cavity was 
subtracted from the total size of the measured lesion. 
Results: As expected, when independent radiology review was 
conducted using RECIST criteria, similar overall response rates were 
conﬁrmed, although individual patients’ response may have changed. 
Signiﬁcant cavitation of pulmonary lesions was seen in approximately 
20% of patients treated with VEGFR inhibitors. The use of the ‘explor-
atory’ response assessment did not signiﬁcantly increase the overall 
number of responses but did lead to an earlier designation of response 
and/or progression in 10% of patients.
Conclusions: The addition of VEGFR inhibitors to platinum-based 
chemotherapy leads to encouraging antitumour activity, sometimes 
with cavitation. The cavitation noted with the use of antiangiogenic 
agents may have implications for response assessment and trial end-
points that rely upon determination of time to disease progression. 
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Background: C225 is a unique monoclonal antibody targeting epidermal 
growth factor receptor. Weekly C225 in combination with standard q 3 
week PacCb yielded a median survival of nearly 11 months in a large 
phase II trial of SWOG (Kelly, ASCO 2006), and is currently being test-
ed in combination with bevacizumab and PacCb. We mounted a phase II 
trial of this agent in combination with monthly Cb and weekly Pac, in an 
effort to capitalize on potential synergy between taxane and C225, and to 
mitigate taxane-induced neuropathy and myalgia/arthralgias. 
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Materials and Methods: Enrollees received Cb AUC 6 day 1 in 
combination with Pac 100 mg/m2 days 1, 8, and 15 every 4 weeks, and 
C225 at a loading dose of 400 mg/m2 day 1, then 250 mg/m2 weekly 
thereafter. C225 was continued as a single agent after 6 full cycles of 
therapy in patients without disease progression or limiting toxicity. 
Eligibility stipulated advanced NSCLC (Stage IV, “wet” and IIIB or 
recurrence after prior surgery/radiation); ECOG performance status 
0-1; measurable tumor, and adequate physiologic indices. 
Results: 53 patients were accrued at FCCC and its OPN partners 
Amongst the ﬁrst 32 patients enrolled, 53% were male; median age 
was 63 years (range 41-86), 47% were PS-0; 6% had received prior RT. 
Overall response rate was 55% (16/29) including one CR; 3 patients 
were not evaluable for response: one was found to have brain mets 
during week 1 and two experienced immediate HSRs. With median po-
tential F/U of ≥ 1 yr, median event-free survival was 5.3 months (n=30) 
and median survival 11.1 months (n=32). 25% (8/32), received 6 cycles 
of chemotherapy with 19% (6/32) going onto maintenance C225. Chief 
grade ≥ 3 attributable adverse events included neutropenia (28%); 
anemia (6%); HSR (9%) acneiform rash (28%) and hypomagnesemia 
(19%). Overall inc. (any grade) of rash was 84% and hypomagnesemia 
47%. Other signiﬁcant toxicities included grade 1-2 paronychia, with 
nail lysis and digital ﬁssures (19%), which tended to be cumulative. 
Conclusions: C225 in combination with monthly Cb and weekly Pac is 
highly active in advanced NSCLC. Response and survival data to date 
are promising. Toxicities match those seen with this PacCb alone, but 
also include persistent hypomagnesemia, and cumulative paronychia 
and nail changes, the latter troublesome, if not treatment-limiting. We 
will report the full results in 9/07.
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Background: CP-751,871 is a fully human, IgG2 monoclonal antibody 
against the Insulin Growth Factor I Receptor (IGF-IR) active in preclin-
ical models of NSCLC. We report the results of an ongoing phase Ib/II 
study in ten centers evaluating the safety and efﬁcacy of the combina-
tion of paclitaxel (T), carboplatin (C) and CP-751,871 (I) in advanced 
NSCLC. 
Methods: Phase Ib was an open-label dose-escalation study of T (200 
mg/m2), C (AUC of 6) and CP-751,871 (0.05-10 mg/kg) every 3 weeks 
for up to 6 cycles in patients with advanced solid malignancies; pts 
with response or stable disease could receive extended CP-751,871 
therapy. The ongoing phase II is an open label, randomized (2:1), 
non-comparative study of TCI versus TC alone. Only treatment-naïve 
NSCLC pts (stage IIIB or IV) are eligible in phase II. The statistical 
hypotheses are 28% (null) versus 40% - response of interest (RR) - for 
TCI. 
Results: Following informed consent and screening, 7 cohorts with a 
total of 30 pts, including 23 NSCLC pts, were enrolled in phase 1b. No 
dose limiting toxicities were identiﬁed and the recommended phase 2 
dose cohort of 10 mg/kg was extended to 12 pts. One case of isolated 
grade 3 GGT elevation attributed to CP-751,871 was reported. An in-
terim analysis for futility has been conducted at 73 pts enrolled in phase 
II: 48 treated with TCI; 25 with TC. TCI was well tolerated. All causal-
ity grade 3, 4 toxicity included (TCI, TC): hyperglycemia (20%, 10%), 
fatigue (15%, 8%), neutropenia (13%, 20%) and neuropathy (10%, 
4%).Twenty-two pts receiving TCI (46%) and 8 pts on TC alone (32%) 
had objective responses. Furthermore, 14 out of 27 TCI pts (52%) with 
non-adenocarcinoma responded to treatment. In addition, a PR was 
observed in 1 out of 4 TC pts who elected to receive single agent I after 
progression on TC alone. 
Conclusions: CP-751,871 appears safe in combination with TC. In-
terim TCI activity has warranted further investigation. An additional 83 
pts will be enrolled in phase II to assess further the safety and efﬁcacy 
of this treatment combination in NSCLC.
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Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral 
anticancer drug that selectively inhibits vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF) and RET (REarranged 
during Transfection) receptor tyrosine kinase activity. Vandetanib was 
evaluated as a monotherapy in a randomized, double-blind, dose-ﬁnd-
ing study in Japan.
Methods: Eligible patients had locally advanced or metastatic (stage 
IIIB/IV) or recurrent NSCLC, after failure of one or two platinum-
based chemotherapy regimens. Patients were randomized to receive 
once-daily oral vandetanib 100, 200 or 300 mg (1:1:1), with stratiﬁca-
tion according to sex, histology (adenocarcinoma vs other histology) 
and smoking status (smoker vs non-smoker). Tumor response was 
assessed by RECIST every 4 weeks for the ﬁrst 24 weeks of treatment 
and then every 8 weeks until progressive disease (PD) or any other 
withdrawal criteria was met. The primary objective was to determine 
the objective response rate (ORR) for each vandetanib dose. Secondary 
assessments included disease control rate (DCR), safety and toler-
ability. Exploratory assessments included analysis of tumor samples 
for ampliﬁcation of EGFR gene copy number (ﬂuorescence in situ 
hybridization [FISH]) and somatic mutations of the EGFR gene, and 
measurement of plasma VEGF levels.
Results: Fifty-three patients (34 males/19 females, median age 60 
years, range 30–78) received vandetanib (100 mg, n=17; 200 mg, n=18; 
300 mg, n=18). The overall ORR was 13.2% (7/53; all partial responses 
[PRs]). The ORR in the vandetanib 100, 200 and 300 mg/day arms 
were 17.6% (3/17), 5.6% (1/18) and 16.7% (3/18), respectively. There 
